Log in
Enquire now
‌

US Patent 11998524 Forms of aticaprant

Patent 11998524 was granted and assigned to Janssen Pharmaceuticals on June, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Janssen Pharmaceuticals
Janssen Pharmaceuticals
0
Current Assignee
Janssen Pharmaceuticals
Janssen Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119985240
Patent Inventor Names
Philippe Fernandes0
Chakradhar Lagishetty0
Wayne C. Drevets0
Vanina Popova0
Adam Savitz0
Srihari Gopal0
Rama Melkote0
Mark Schmidt0
...
Date of Patent
June 4, 2024
0
Patent Application Number
181789610
Date Filed
March 6, 2023
0
Patent Citations
‌
US Patent 7396943 Opioid receptor antagonists
0
‌
US Patent 7399774 6-substituted nicotinamide derivatives as opioid receptor antagonists
0
‌
US Patent 7414132 Opioid receptor antagonists
0
‌
US Patent 7531557 Diaryl ethers as opioid receptor antagonists
0
‌
US Patent 7560463 Diaryl ethers as opioid receptor antagonists
0
‌
US Patent 7709522 Kappa selective opioid receptor antagonist
0
‌
US Patent 8063059 Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders
0
‌
US Patent 8173695 Kappa selective opioid receptor antagonist
0
...
Patent Primary Examiner
‌
Matthew P Coughlin
0
CPC Code
‌
C07B 2200/13
0
‌
A61P 25/24
0
‌
A61K 31/40
0
Patent abstract

The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11998524 Forms of aticaprant

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.